Wuhan Healthgen Biotechnology Corp. (SHA:688765)
China
· Delayed Price · Currency is CNY 71.82
+1.49 (2.12%)
At close: Mar 6, 2026
SHA:688765 Revenue
Wuhan Healthgen Biotechnology had revenue of 12.71M CNY in the half year ending June 30, 2025, with 595.14% growth. This brings the company's revenue in the last twelve months to 23.39M, down -3.62% year-over-year. In the year 2024, Wuhan Healthgen Biotechnology had annual revenue of 25.22M with 3.92% growth.
Revenue (ttm)
23.39M
Revenue Growth
-3.62%
P/S Ratio
1,089.15
Revenue / Employee
131.39K
Employees
215
Market Cap
25.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.22M | 952.02K | 3.92% |
| Dec 31, 2023 | 24.26M | 10.86M | 81.08% |
| Dec 31, 2022 | 13.40M | -12.12M | -47.49% |
| Dec 31, 2021 | 25.52M | 3.95M | 18.33% |
| Dec 31, 2020 | 21.57M | 11.32M | 110.40% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LAPLACE Renewable Energy Technology | 5.46B |
| HMT (Xiamen) New Technical Materials | 2.46B |
| Shanghai Construction Group | 244.28B |
| Suzhou Novosense Microelectronics | 3.37B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| State Grid Information & Communication | 10.63B |
| Jiangsu Boqian New Materials Stock | 1.02B |
| Minmetals Capital Company | 5.01B |